Concluding Remarks
Hyperkalemia is a common electrolyte abnormality after KT with an incidence ranging from 25-44% in KT recipients on CNIs.[2] In KT patients, factors such as tubular dysfunction and various drug classes may increase the risk of hyperkalemia. Limited data exist in the kidney transplant population on the management of hyperkalemia. Our recommendations are mainly based on data from studies in patients with CKD. Nevertheless, KT patients by definition have CKD and the approach to treating hyperkalemia should be generally the same. Understanding the pathophysiology, treatment options, as well as limitations are all key to the successful treatment and prevention of hyperkalemia post-kidney transplant.